Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.

Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19. Int J Hematol. 2020 May 12;: Authors: Takami A PMID: 32399895 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32399895?dopt=Abstract

Source: International Journal of Hematology - May 11, 2020 Category: Hematology Authors: Takami A Tags: Int J Hematol Source Type: research

More News: COVID-19 | Hematology